Diffraction data were collected to a limiting resolution of 2.4 Å from a crystal of selenomethionyl-labelled SadA, an l-amino-acid dioxygenase.
Keywords: C3-hydroxylation, dioxygenases, N-succinyl-l-leucine
Abstract
Ferrous ion- and α-ketoglutarate-dependent dioxygenase from Burkholderia ambifaria AMMD (SadA) catalyzes the C3-hydroxylation of N-substituted branched-chain l-amino acids, especially N-succinyl-l-leucine, coupled to the conversion of α-ketoglutarate to succinate and CO2. SadA was expressed in Escherichia coli, purified and crystallized using the sitting-drop vapour-diffusion method at 293 K. Crystals of selenomethionine-substituted SadA were obtained using a reservoir solution containing PEG 3000 as the precipitant at pH 9.5 and diffracted X-rays to 2.4 Å resolution. The crystal belonged to space group P212121, with unit-cell parameters a = 49.3, b = 70.9, c = 148.2 Å. The calculated Matthews coefficient (V M = 2.1 Å3 Da−1, 41% solvent content) suggested that the crystal contains two molecules per asymmetric unit.
1. Introduction
The ferrous ion- and α-ketoglutarate-dependent dioxygenases can catalyze the hydroxylation of proteins, nucleic acids, lipids and small molecules (McDonough et al., 2010 ▶). These enzymes participate in a vast array of protein side-chain modifications, repair of alkylated DNA/RNA, biosynthesis of antibiotics and plant products and so on (Hausinger, 2004 ▶). The enzymatic hydroxylation of prolyl and lysyl residues is a well known post-translational modification (Prockop & Kivirikko, 1995 ▶) and the related human dioxygenases have been proposed as targets in cancer treatment (Shi, 2007 ▶). Asymmetric synthesis is increasingly being targeted for drug synthesis, which can benefit greatly from the selectivity gains associated with enzymatic catalysis (Matsuda et al., 2009 ▶; Savile et al., 2010 ▶). For example, l-isoleucine dioxygenase from Bacillus thuringiensis can stereoselectively hydroxylate l-Ile to (2S,3R,4S)-4-hydroxyisoleucine, a natural nonproteinogenic amino acid which has insulinotropic and anti-obesity effects and appears to be a potential drug for diabetes (Kodera et al., 2009 ▶).
Hydroxylation reactions as catalyzed by dioxygenases require dioxygen as well as ferrous ion (FeII) and α-ketoglutarate (α-KG). One of the O atoms is incorporated into the substrate to form a hydroxyl amino acid, while the other O atom is used to oxidatively break down α-KG into succinate and CO2. Structural analyses have revealed that this family of enzymes possess a common protein fold called the double-stranded β-helix (DSBH) fold as the core of the structure and an HXD/EX nH motif in the active site that coordinates the FeII cofactor (Chowdhury et al., 2009 ▶; Clifton et al., 2006 ▶; McDonough et al., 2010 ▶; Strieker et al., 2007 ▶). However, there is much greater variation in the secondary substrate-binding sites, which define the substrate specificity and stereoselectivity of the hydroxylation reaction.
SadA is a member of the dioxygenase family from Burkholderia ambifaria AMMD and consists of 273 amino-acid residues (30 664 Da). This enzyme catalyzes (R)-selective hydroxylation at the C3 position of N-substituted branched-chain l-amino acids, especially N-succinyl-l-leucine, from which N-succinyl-(R)-3-hydroxy-l-leucine is produced with >99% diastereoselectivity (Hibi et al., unpublished data). (R)-3-Hydroxy-l-leucine in particular is a promising target material for the preparation of certain cyclic depsipeptides (Taniguchi et al., 2003 ▶; Tymiak et al., 1989 ▶). SadA is the first enzyme that has been shown to catalyze the C3-hydroxylation of aliphatic amino-acid-related substances. Sequence alignment shows that SadA has low sequence identity to other members of the family (12% sequence identity to PHD2; PDB entry 3hqr; Chowdhury et al., 2009 ▶). However, the structure of SadA has not been determined. Therefore, high-resolution crystal structure analysis will be required in order to elucidate its stereoselective reaction mechanism.
Here, we report the expression, purification, crystallization and preliminary X-ray analysis of SadA in order to elucidate the structural basis of its stereoselective hydroxylation and substrate specificity. Determination of the structure of SadA may help us to better understand the relationship between its structure and function. Furthermore, SadA may be utilized as an industrial enzyme for the manufacture of pharmaceuticals on a commercial scale in the future.
2. Materials and methods
2.1. Overexpression and purification
The SadA gene (GenBank accession No. YP_777923) was cloned into pQE80 vector (Qiagen) between the BamHI and HindIII sites. The expressed SadA protein was fused to a hexahistidine (His6) tag (MRGSHHHHHHGS) at the N-terminus. Escherichia coli Rosetta (DE3) cells (Novagen) were transformed with the plasmid and were grown in lysogeny broth (LB) medium containing 100 µg ml−1 ampicillin and 34 µg ml−1 chloramphenicol at 310 K. When the OD600 reached 0.5, the cells were transferred into M9 medium supplemented with 50 µg ml−1 selenomethionine (SeMet). The culture was cooled to 298 K, isopropyl β-d-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM and the culture was further incubated at 298 K overnight.
The cells were harvested by centrifugation and disrupted by sonication in resuspension buffer (20 mM Tris–HCl pH 8.0, 10 mM imidazole, 0.5 M NaCl, 1 mM dithiothreitol). The cell debris was removed by centrifugation and filtration. SeMet-substituted SadA (SadASeMet) in the solution was trapped on Ni–NTA Superflow resin (Qiagen) using the His6 tag. After washing, the His6-tagged protein was eluted with resuspension buffer containing 200 mM imidazole. The eluted solution was dialyzed against 20 mM Tris–HCl pH 8.0, 1 mM dithiothreitol, and the SadASeMet was further purified using Resource Q (GE Healthcare). The solution containing purified SadASeMet, from which the His6 tag had not been cleaved, was concentrated to 15 mg ml−1 using Vivaspin-20 (10 000 molecular-weight cutoff) prior to crystallization trials.
2.2. Crystallization
Crystallization of SadASeMet was carried out with the sparse-matrix screening kits Crystal Screen HT (Hampton Research), Index HT (Hampton Research) and Wizard I and II (Emerald BioSystems) in 96-well plates using the sitting-drop vapour-diffusion method. For refinement of the crystallization conditions, 1 µl protein solution was mixed with an equal volume of reservoir solution and equilibrated against 0.5 ml reservoir solution at 293 K in 24-well plates (Hampton Research).
2.3. X-ray data collection and processing
X-ray diffraction data were collected from a SadASeMet crystal on the BL-17A beamline at Photon Factory, Tsukuba, Japan. The wavelength (0.97894 Å) for data collection was determined from the selenium absorption spectrum. The single-wavelength anomalous diffraction (SAD) data set for the SadASeMet crystal was composed of 720 images and was collected using a 0.5° oscillation with a crystal-to-detector distance of 361.6 mm and an exposure time of 2 s for each image. All diffraction data were indexed, integrated and scaled with HKL-2000 (Otwinowski & Minor, 1997 ▶).
3. Results and discussion
SadASeMet was expressed in E. coli and purified by affinity-resin and anion-exchange chromatography. Crystals of SadASeMet were obtained using a reservoir solution consisting of 30%(w/v) PEG 3000, 0.1 M CHES pH 9.5 at 293 K. Fig. 1 ▶ shows a typical crystal 3 d after initiation of crystallization, with approximate dimensions of 0.10 × 0.20 × 0.15 mm. X-ray diffraction data were collected to 2.4 Å resolution. Fig. 2 ▶ shows an X-ray diffraction image of the SadASeMet crystal. The crystal belonged to space group P212121, with unit-cell parameters a = 49.3, b = 70.9, c = 148.2 Å. 20 990 unique reflections were collected in the resolution range 20−2.40 Å with 100% completeness and an R merge of 8.7%. The data-collection and processing statistics are summarized in Table 1 ▶. Matthews analysis suggested that there were two molecules per asymmetric unit in the SadA crystal (Matthews coefficient of 2.1 Å3 Da−1, 41% solvent content; Matthews, 1968 ▶). Determination of the three-dimensional structure will be performed by the SAD method using the data set from the SadASeMet crystal. The protein structure obtained by X-ray crystallography will be utilized to characterize the substrate-binding site of SadA.
Figure 1.

Typical crystal of SadASeMet grown at 293 K using 30%(w/v) PEG 3000 as the precipitant at pH 9.5. The crystal has approximate dimensions of 0.10 × 0.20 × 0.15 mm.
Figure 2.
An X-ray diffraction image (0.5° oscillation) from the SadASeMet crystal. The edge of the detector corresponds to 2.4 Å resolution (indicated by the circle).
Table 1. Data-collection statistics for SadASeMet .
Values in parentheses are for the highest resolution shell.
| Beamline | BL-17A, Photon Factory |
| Wavelength (Å) | 0.97894 |
| Space group | P212121 |
| Unit-cell parameters (Å) | a = 49.3, b = 70.9, c = 148.2 |
| Resolution (Å) | 20–2.40 (2.44–2.40) |
| Unique reflections | 20990 (1041) |
| Multiplicity | 14.3 (14.2) |
| Completeness (%) | 100 (100) |
| R merge † | 0.087 (0.423) |
| 〈I/σ(I)〉 | 64.2 (7.8) |
R
merge =
, where Ii(hkl) is the ith intensity measurement of reflection hkl, including symmetry-related reflections, and 〈I(hkl)〉 is its average.
Acknowledgments
We would like to thank the scientists and staff at the Photon Factory. The synchrotron-radiation experiments were performed on the BL-17A beamline at the Photon Factory, Tsukuba, Japan (Proposal No. 2008S2-001). This work was supported by the Targeted Proteins Research Program (TPRP) of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
References
- Chowdhury, R., McDonough, M. A., Mecinović, J., Loenarz, C., Flashman, E., Hewitson, K. S., Domene, C. & Schofield, C. J. (2009). Structure, 17, 981–989. [DOI] [PubMed]
- Clifton, I. J., McDonough, M. A., Ehrismann, D., Kershaw, N. J., Granatino, N. & Schofield, C. J. (2006). J. Inorg. Biochem. 100, 644–669. [DOI] [PubMed]
- Hausinger, R. P. (2004). Crit. Rev. Biochem. Mol. Biol. 39, 21–68. [DOI] [PubMed]
- Kodera, T., Smirnov, V. S., Samsonova, N. N., Kozlov, I. Y., Koyama, R., Hibi, M., Ogawa, J., Yokozeki, K. & Shimizu, S. (2009). Biochem. Biophys. Res. Commun. 390, 506–510. [DOI] [PubMed]
- Matsuda, T., Yamanaka, R. & Nakamura, K. (2009). Tetrahedron Asymmetry, 20, 513–557.
- Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
- McDonough, M. A., Loenarz, C., Chowdhury, R., Clifton, I. J. & Schofield, C. J. (2010). Curr. Opin. Struct. Biol. 20, 659–672. [DOI] [PubMed]
- Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
- Prockop, D. J. & Kivirikko, K. I. (1995). Annu. Rev. Biochem. 64, 403–434. [DOI] [PubMed]
- Savile, C. K., Janey, J. M., Mundorff, E. C., Moore, J. C., Tam, S., Jarvis, W. R., Colbeck, J. C., Krebber, A., Fleitz, F. J., Brands, J., Devine, P. N., Huisman, G. W. & Hughes, G. J. (2010). Science, 329, 305–309. [DOI] [PubMed]
- Shi, Y. (2007). Nature Rev. Genet. 8, 829–833. [DOI] [PubMed]
- Strieker, M., Kopp, F., Mahlert, C., Essen, L. O. & Marahiel, A. M. (2007). ACS Chem. Biol. 2, 187–196. [DOI] [PubMed]
- Taniguchi, M., Suzumura, K. I., Nagai, K., Kawasaki, T., Saito, T., Takasaki, J., Suzuki, K. I., Fujita, S. & Tsukamoto, S. I. (2003). Tetrahedron, 59, 4533–4538.
- Tymiak, A. A., McCormick, T. J. & Unger, S. E. (1989). J. Org. Chem. 54, 1149–1157.

